Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1994 1
1995 1
1996 1
1997 1
2001 2
2016 1
2017 3
2018 2
2019 10
2020 10
2021 10
2022 9
2023 9
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Differential Immunoexpression of Inhibitory Immune Checkpoint Molecules and Clinicopathological Correlates in Keratoacanthoma, Primary Cutaneous Squamous Cell Carcinoma and Metastases.
Lonsdorf AS, Edelmann D, Albrecht T, Brobeil A, Labrenz J, Johanning M, Schlenk RF, Goeppert B, Enk AH, Toberer F. Lonsdorf AS, et al. Among authors: edelmann d. Acta Derm Venereol. 2024 Feb 7;104:adv13381. doi: 10.2340/actadv.v104.13381. Acta Derm Venereol. 2024. PMID: 38323498 Free PMC article.
CpG-biomarkers in tumor tissue and prediction models for the survival of colorectal cancer: A systematic review and external validation study.
Yuan T, Edelmann D, Kather JN, Fan Z, Tagscherer KE, Roth W, Bewerunge-Hudler M, Brobeil A, Kloor M, Bläker H, Burwinkel B, Brenner H, Hoffmeister M. Yuan T, et al. Among authors: edelmann d. Crit Rev Oncol Hematol. 2024 Jan;193:104199. doi: 10.1016/j.critrevonc.2023.104199. Epub 2023 Nov 11. Crit Rev Oncol Hematol. 2024. PMID: 37952858 Review.
Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease.
Heitmann JS, Schlenk RF, Dörfel D, Kayser S, Döhner K, Heuser M, Thol F, Kapp-Schwoerer S, Labrenz J, Edelmann D, Märklin M, Vogel W, Bethge W, Walz JS, Große-Hovest L, Steiner M, Jung G, Salih HR. Heitmann JS, et al. Among authors: edelmann d. J Hematol Oncol. 2023 Aug 17;16(1):96. doi: 10.1186/s13045-023-01490-w. J Hematol Oncol. 2023. PMID: 37587502 Free PMC article. Clinical Trial.
Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.
Park HA, Edelmann D, Canzian F, Seibold P, Harrison TA, Hua X, Shi Q, Silverman A, Benner A, Macauda A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Park HA, et al. Among authors: edelmann d. Int J Cancer. 2023 Nov 1;153(9):1623-1634. doi: 10.1002/ijc.34663. Epub 2023 Aug 4. Int J Cancer. 2023. PMID: 37539667 Free PMC article.
56 results